Biomarkers for Lung Disease Including COPD, Pulmonary Fibrosis and Lung Cancer
Studies blood markers in adults with COPD, pulmonary fibrosis or lung cancer.
Plain-language title generated from the registry record
Registry title: Identification of Diagnostic and Prognostic Biomarkers in the Pathological Continuum of Bronco Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis and Pulmonary Neoplasia
Key facts
- Where
- Milan, ItalySee the site
Where in Italy
- IRCCS Fondazione Don Carlo GnocchiMilan, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fondazione Don Carlo Gnocchi ETS
- Trial code
- NCT07707245
- Record updated
- 16 July 2026
- Original description
Primary Objective:Read full original descriptionShow less
Identification of Diagnostic and Prognostic Biomarkers in the Pathological Continuum of Bronco Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis and Pulmonary Neoplasia
Primary Objective:
To evaluate the association between inflammatory, immunological, genetic, and epigenetic biomarkers measured at enrollment and the clinical, functional, and phenotypic characteristics of patients with chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and lung cancer.
Secondary Objective:
To assess the prognostic value of the identified biomarkers by evaluating their ability to predict clinical outcomes at 12 months.
Primary Outcome Measure:
Association between baseline inflammatory, immunological, genetic, and epigenetic biomarkers and disease-specific clinical, functional, and phenotypic characteristics assessed at enrollment, including:
COPD: current or former smokers, stratified according to the predominant phenotype (emphysema or bronchiolitis); IPF: rapid progressors, slow progressors, and patients with combined pulmonary fibrosis and emphysema (CPFE); Lung cancer: current smokers, former smokers who quit less than 15 years before enrollment, former smokers who quit 15 years or more before enrollment, and never-smokers.
Secondary Outcome Measure:
Predictive performance of baseline inflammatory, immunological, genetic, and epigenetic biomarkers for 12-month clinical outcomes.
Inclusion: Age ≥ 18 years; Clinical diagnosis of: Chronic Obstructive Pulmonary Disease (COPD), current or former smokers; and/or Idiopathic Pulmonary Fibrosis (IPF), current or former smokers; and/or Resectable lung adenocarcinoma (Stage I-III, according to clinical indication for surgical resection); Ability to comply with study procedures and follow-up visits.
Exclusion: Previous or concomitant malignant disease (except non-melanoma skin cancer) that could interfere with study objectives; Prior systemic immunosuppressive or anti-inflammatory therapy that may significantly alter immune profiling within a defined washout period (if applicable per protocol); Active respiratory infection or acute exacerbation of COPD or IPF at the time of enrollment; Severe comorbid conditions limiting life expectancy or ability to complete follow-up (e.g., advanced heart failure, severe renal or hepatic disease); Inadequate biological sample quality or impossibility to obtain required blood samples; Inability or unwillingness to provide informed consent.